| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H28FN5O2 |
| Molecular Weight | 365.4456 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CN(C[C@]1([H])C[C@](C)(C2)NCC(=O)N3C[C@@H](F)C[C@H]3C#N)C(=O)N(C)C
InChI
InChIKey=WWRKIQZKFGMESZ-SFUJAXRZSA-N
InChI=1S/C18H28FN5O2/c1-18(21-8-16(25)24-11-14(19)4-15(24)7-20)5-12-9-23(10-13(12)6-18)17(26)22(2)3/h12-15,21H,4-6,8-11H2,1-3H3/t12-,13+,14-,15-,18+/m0/s1
| Molecular Formula | C18H28FN5O2 |
| Molecular Weight | 365.4456 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Jiangsu HengRui Medicine Co. is developing SHR-117887, an orally active dipeptidyl peptidase-4 (CD26 antigen) inhibitor for the treatment of type 2 diabetes. SHR-117887 is a potent DPP-4 inhibitor that improves metabolic control and β-cell function in diabetic rodent models. SHR-117887 is in phase II clinical trials for the treatment of type 2 diabetes.
Originator
Approval Year
PubMed
Sample Use Guides
Type 2 Diabetes:
Experimental: SHR-117887 (50mg q.d)/Metformin
Patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period. After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
Experimental: SHR-117887 (100mg q.d)/Metformin
patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised, patients adminitered SHR-117887 100mg QD and metformin 500mg TID for 12 weeks.
Route of Administration:
Oral
